U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905561) titled 'Topical Diclofenac for Prevention of Radiation-induced Dermatitis' on Feb. 07.
Brief Summary: Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development ...